Clinical Trial: Safety and Activity of HF50 in Patients With Advanced Solid Tumors

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07601334) titled 'Safety and Activity of HF50 in Patients With Advanced Solid Tumors' on May 15.

Brief Summary: A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.

Study Start Date: June 30

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: HF50

HF50 is an innovative liposome-encapsulated bifunctional therapeutic designed to redirect T-cells to HER2-expressing tumor cells while simultaneously activating innate immunity through TLR7/8 agonism.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: HighField Biopharmaceuticals Corporation

Published by HT Dig...